Dan L Duncan Comprehensive Cancer Center at Baylor St. Luke’s Medical Center serves as a decision support resource to further clinical insights in complex oncology medical cases where NGS or germline molecular testing may be needed. The Molecular Tumor Board supplements existing institutional resources by placing molecular diagnostic data in context with other patient data and providing expert guidance to care providers. Additionally, in expanding participation to local and national research groups, the MTB may aid in the facilitation of patient recruitment to clinical trials.
Who Are We?
Delivering precision medicine insight using tumor sequencing is a complex process. Thanks to a partnership with Dan L Duncan Comprehensive Cancer Center at Baylor St. Luke’s Medical Center and Baylor College of Medicine we can provide clinical expertise in the interpretation of genetic testing with the functional services of the virtual Molecular Tumor Board (MTB).
Our board members include molecular pathologists, medical oncologists, medical geneticists, genetic counselors, pharmacists, and research staff.
How Often Does the Tumor Board Meet?
Currently, the MTB meets monthly, reviewing complex cases. For time-sensitive or urgent cases, ad hoc meetings can be arranged. Fellow clinicians and research staff are welcome to attend open meetings.
The MTB welcomes all patient case submissions from physicians affiliated with St. Luke’s Health. All submissions are processed in a HIPAA-complaint manner.
For submissions please fill out the form below. For questions please email firstname.lastname@example.org
Ashok Balasubramanyam, M.D.
Vice President, Academic Integration
Baylor College of Medicine
Quillan Huang, M.D.
Dan L Duncan Comprehensive Cancer Center